Related Experiment Videos
An integrated evidence rating to frame comparative effectiveness assessments for decision makers
Daniel A Ollendorf1, Steven D Pearson
1Institute for Clinical and Economic Review (ICER), Massachusetts General Hospital Institute for Technology Assessment, Boston, MA 02114, USA.
Medical Care
|May 18, 2010
Summary
Comparative effectiveness reviews are challenging to translate for stakeholders. The Institute for Clinical and Economic Review (ICER) developed integrated evidence ratings to improve understanding and application of health care value and effectiveness findings.
Area of Science:
- Health Services Research
- Health Economics
- Evidence-Based Medicine
Background:
- Comparative effectiveness reviews (CERs) face challenges in translating findings for practical use by stakeholders.
- Improving the quality and value of healthcare requires actionable guidance from research.
Purpose of the Study:
- To present the Institute for Clinical and Economic Review's (ICER) integrated evidence rating system.
- To enhance the utility and understanding of CERs for diverse decision-makers.
Main Methods:
- ICER employs integrated evidence ratings combining comparative clinical effectiveness and value assessments.
- These ratings are designed to resemble bond ratings for easier interpretation.
- The system aims to facilitate application in patient information, clinical guidelines, and policy development.
Main Results:
- ICER's integrated ratings have informed coverage decisions for some payers.
- Demonstration projects are exploring links between reviews, patient information, and payment policies.
- Feedback indicates the rating format aids understanding of comparative effectiveness judgments.
Conclusions:
- Decision-makers require objective, rigorous CERs with clearly translated judgments.
- A rating system for comparative clinical effectiveness and value can improve CER understandability and utility.
- This approach aims to make CERs more accessible and actionable for all stakeholders.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:09Odds Ratio
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...